Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of epcoritamab + rituximab + lenalidomide versus chemoimmunotherapy in previously untreated follicular lymphoma
jRCT2071240034Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epcoritamab, rituximab, lenalidomide, obinutuzumab, cyclophosphamide and 4 more in follicular lymphoma (FL) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Complete response rate at 30 months and Progression-free survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
epcoritamabrituximablenalidomideobinutuzumabcyclophosphamide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2071240034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240034.